TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. ACN
5. AZN
6. ROIV
7. AAPL
8. QCOM
9. NVDA
10. USO

Go back to TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Amgen Inc (NASDAQ: AMGN) Delayed: 395.83 -41.4 (9.47%)
Previous Close $437.23    52 Week High $176.85 
Open $408.90    52 Week Low $133.64 
Day High $410.03    P/E 59.61 
Day Low $392.00    EPS $6.64 
Volume 3,120,472